Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5959
    +0.0009 (+0.15%)
     

  • NZD/EUR

    0.5544
    +0.0004 (+0.07%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    83.63
    +0.06 (+0.07%)
     

  • GOLD

    2,360.80
    +18.30 (+0.78%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,106.51
    +27.65 (+0.34%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,044.45
    +127.17 (+0.71%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.1940
    +0.6980 (+0.75%)
     

Sema4 to Participate at Two Investor Conferences in June 2022

Sema4 Holdings Corp.
·1-min read
Sema4 Holdings Corp.
Sema4 Holdings Corp.

STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following investor conferences:

  • Conference: Jefferies Healthcare Conference 
    Format: Fireside chat and 1x1s 
    Presentation Date/Time: Thursday, June 9th, 2022 at 8:30 a.m. ET

  • Conference: Goldman Sachs 43rd Annual Global Healthcare Conference 
    Format: Fireside chat and 1x1s 
    Presentation Date/Time: Thursday, June 16th, 2022 at 12:20 p.m. ET / 9:20 a.m. PT

Live and archived webcasts of the presentations will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.

ADVERTISEMENT

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Investor Relations Contact:
Joel Kaufman
Sema4
investors@sema4.com

Media Contact:
Radley Moss
Sema4
radley.moss@sema4.com